Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients with Acute Ischemic STROKE

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

5,138

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Ischemic StrokeClopidogrel Resistance
Interventions
DRUG

The ticagrelor

Ticagrelor 90mg should be taken as soon as possible. From the 2nd to the 21st day, the patient should receive dual anti - platelet therapy with ticagrelor 90mg twice a day (bid) combined with aspirin 100mg once a day (qd). From the 22nd to the 90th day, the patient should be given ticagrelor 90mg bid for anti - platelet treatment.

DRUG

The Clopidogrel

From the 2nd to the 21st day, the patient should receive dual anti - platelet therapy with clopidogrel 75mg once a day (qd) combined with aspirin 100mg once a day (qd). From the 22nd to the 90th day, the patient should be given clopidogrel 75mg qd for anti - platelet treatment.

Trial Locations (1)

610072

Sichuan Provincial People's Hospital, Chengdu

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Chengdu Medical College

OTHER

lead

Sichuan Provincial People's Hospital

OTHER

NCT06853535 - Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients with Acute Ischemic STROKE | Biotech Hunter | Biotech Hunter